VA-MD-SES
Today, Thales, SES S.A. and Hughes Network Systems (HUGHES) announced a set of strategic agreements to enhance the delivery of FlytLIVETM – Thales' connected inflight experience solution, offering the most advanced and efficient aeronautical connectivity solution available in the Americas. Under the agreements, SES contracts capacity on Hughes EchoStar XVII and EchoStar XIX high throughput (HTS) Ka-band satellites to complement its AMC-15 and AMC-16 network giving FlytLIVE the only redundant coverage network in North America. SES will also purchase multiple JUPITER™ System gateways from Hughes to qualify Thales to deploy its FlytLIVE service on Hughes JUPITER Aeronautical platform. This will allow Thales to initiate its next-generation connected inflight experience offering in North America this year.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170307006625/en/
Furthermore, the system being deployed is forward compatible with SES-17, SES' powerful Ka-band HTS satellite optimized for aviation connectivity and expected to launch in 2020, thus ensuring Thales’ airline clients have a clear and effective path for accommodating the ever-growing traffic demands of their passengers.
FlytLIVE by Thales provides an advanced, seamless inflight connectivity solution with unmatched performance and redundancy, giving passengers the full broadband Internet connectivity, including the ability to stream Internet services for video, games, social media and live television, creating an immersive and engaging experience in the air. In addition, this new service enables airlines to upload content, download operational data, and provide live television channels to their entire fleet through managed end-to-end solutions and network services.
In 2016, SES and Thales announced an agreement to procure and commercialize SES-17 and to leverage SES' existing AMC-15 and AMC-16 satellites for FlytLIVE. This new set of strategic agreements between SES, Thales and Hughes provide Thales with an expanded scope of HTS Ka-band satellite capacity and the latest and most advanced aeronautical platform available today. The combination of Hughes EchoStar XVII and XIX Ka-band satellites with SES’ AMC-15 and AMC-16 network provide for expanded satellite capacity, coverage, and redundancy over North America. With these four satellites and the Hughes JUPITER System aeronautical platform, Thales will be positioned to offer the most comprehensive connectivity and content services for the full gamut of North American flight routes, including routes between the North East U.S. and Canada and the Caribbean, which to-date have been underserved as these flight routes are predominantly over open ocean. This combination of coverage, performance, redundancy, and network robustness will be unique to FlytLIVE.
At the center of the new service is Hughes high-performance JUPITER system that is already in operation for broadband enterprise and consumer services in other major markets globally and will be introduced for aeronautical use on the Thales FlytLIVE network. Unique features of the network include rapid beam-to-beam and satellite-to-satellite switching and DVB-S2x transmission. Thales has already begun service testing using its new Thales Ka-band aero antenna and the Hughes JUPITER technology.
SES will also purchase multiple Hughes JUPITER System gateways to support traffic carried over AMC-15 and AMC-16, as well as SES-17, when it enters service. FlyLIVE’s network will deliver industry leading speed and capacity for support of growing passenger service demands and will comfortably accommodate forecasted traffic increases through the launch of SES-17, which is manufactured by Thales Alenia Space and configured with close to 200 spot beams and coverage tailored to aviation and mobility markets.
“Our experience and position as a global leader in satellites, avionics, cybersecurity and connected inflight entertainment means we are able to deliver the most capable solutions our customers expect. With these strategic agreements with SES and Hughes, Thales FlytLIVE service will be uniquely able to deliver airlines and their passengers with an unsurpassed, connected inflight entertainment experience.”
- Dominique Giannoni, CEO, Thales InFlyt Experience
“This agreement confirms once again SES’s ability to provide scalable solutions tailored to match our customers' specific requirements. Not only are we developing SES-17, a next-generation satellite that Thales will use to meet the future inflight connectivity demands of the next decade, but we are also providing a superior, tailor-made, multi-satellite and multi-beam solution today, in 2017, utilizing assets already in orbit. This is only possible thanks to the combination of our existing robust and flexible network with our long-standing relationship with Hughes and Thales.”
- Elias Zaccack, Senior Vice President of SES’s Global Mobility Team and the Americas region, SES S.A.
“Hughes is proud to join with Thales and SES to bring our advanced JUPITER System aeronautical platform, along with the enhanced satellite coverage and capacity of our EchoStar XVII and XIX satellites, to facilitate the launch and operation of FlytLIVE’s North American service. Our JUPITER platform will enable SES and Thales to deliver an unmatched level of inflight connectivity customer experience, and the capacity brought through our satellites will ensure that Thales’ airline clients will be able to readily accommodate the ever-growing demands and performance expectations of their passengers.”
- Paul Gaske, Executive Vice President, North America, Hughes
About Thales
Thales is a global technology leader for the Aerospace, Transport, Defense and Security markets. With 62,000 employees in 56 countries, Thales reported sales of $15.5 billion in 2015. With over 20,000 engineers and researchers, Thales has a unique capability to design and deploy equipment, systems and services to meet the most complex security requirements. Thales' unique international footprint allows it to work closely with customers all over the world.
About SES S.A.
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at: www.ses.com
About Hughes Network Systems
Hughes Network Systems, LLC (HUGHES) is the global leader in broadband satellite technology and services for home and office. Its flagship high-speed satellite Internet service is HughesNet®, the world’s largest satellite network with over 1 million residential and business customers across North America and Brazil. For large enterprises and governments, the company’s HughesON® managed network services provide complete connectivity solutions employing an optimized mix of satellite and terrestrial technologies. The JUPITER™ System is the world’s most widely deployed High-Throughput Satellite (HTS) platform by leading providers operating on more than 20 satellites, delivering a wide range of enterprise, mobility and cellular backhaul applications. To date, Hughes has shipped more than 5.5 million satellite systems to customers in over 100 countries, representing approximately 50 percent market share, and its technology is powering broadband services to aircraft around the world.
Headquartered outside Washington, D.C., in Germantown, Maryland, USA, Hughes operates sales and support offices worldwide, and is a wholly owned subsidiary of EchoStar Corporation (NASDAQ: SATS), a premier global provider of satellite operations. For additional information about Hughes, please visit www.hughes.com and follow @Hughes_Corp on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307006625/en/
Contact:
Thales
Adam Kostecki
+1 703-838-5645
adam.kostecki@us.thalesgroup.com
or
SES
Markus
Payer
Tel. +352 710 725 500
Markus.Payer@ses.com
or
Hughes
Network Systems
Doug Gunster
+1-301-428-2785
doug.gunster@hughes.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom